Investors should monitor the upcoming Phase 3 CHAPTER-3 topline data in Q3 2026 as the next major catalyst; successful results could drive significant upside given the lack of oral options in HAE and strong Phase 2/3 signals to date.
Price Chart
Executive Summary
Pharvaris announced the publication of positive Phase 2 data from its CHAPTER-1 and RAPIDe-1 trials in The Lancet Haematology, showing deucrictibant's efficacy and safety as both a prophylactic and on-demand oral treatment for hereditary angioedema (HAE). The results support its potential as a first-in-class oral B2 receptor antagonist for end-to-end HAE management, with Phase 3 topline data expected in Q3 2026.
Key Facts
- Phase 2 CHAPTER-1 trial showed statistically significant reduction in HAE attack frequency with deucrictibant for prophylaxis.
- Phase 2 RAPIDe-1 trial demonstrated statistically significant reduction in attack severity and faster symptom relief for on-demand treatment.
- Deucrictibant is an oral bradykinin B2 receptor antagonist, positioning it as a potential first-in-class oral therapy for both prevention and acute treatment of HAE.
- Topline data from pivotal Phase 3 RAPIDe-3 trial already confirmed faster symptom relief and single-capsule resolution in most attacks.
- Marketing authorization applications for deucrictibant immediate-release capsule are being prepared, with NDA submission expected in first half of 2026.
- Deucrictibant has orphan drug designation in the U.S., EU, and Switzerland.
Financial Impact
Potential blockbuster revenue if approved, given deucrictibant's dual indication and oral convenience in a chronic, high-cost rare disease market.
Risk Factors
- Phase 3 data may not replicate Phase 2 results, particularly in larger, more diverse populations.
- Regulatory delays or rejections despite strong data, especially given the novelty of the oral B2 antagonist mechanism.
- Competition from existing injectable therapies and emerging oral kallikrein inhibitors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259646 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $38.06 $36.37 | ▲ +4.44% | ▲ +5.26% | $31.07 (+18.38%) |
Sep 14, 2026 17d ago | 144 | $38.06 $35.20 | ▼ −7.51% | ▼ −9.63% | $31.07 (−18.38%) |
Sep 14, 2026 18d ago | Insider Cluster | $38.86 $36.02 | ▼ −7.31% | ▼ −7.41% | $31.07 (−20.06%) |
Sep 11, 2026 21d ago | Insider Cluster | $38.02 $36.37 | ▼ −4.34% | ▼ −4.12% | $31.07 (−18.29%) |
Sep 8, 2026 24d ago | 6-K | $37.84 $38.86 | ▲ +2.70% | ▲ +3.36% | $31.07 (−17.90%) |
Aug 12, 2026 7w ago | 6-K | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 12, 2026 7w ago | Press Release | $36.46 $36.27 | ▼ −0.52% | ▼ −0.08% | $31.07 (−14.80%) |
Aug 6, 2026 8w ago | Press Release | $34.45 $34.04 | ▼ −1.19% | ▼ −2.40% | $31.07 (−9.83%) |
Jul 6, 2026 12w ago | Press Release | $33.22 $35.07 | ▲ +5.57% | ▲ +5.08% | $31.07 (−6.49%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.86 $35.96 | ▲ +6.20% | ▲ +5.27% | $31.07 (−8.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access